Skip to main content

Sangamo BioSciences (SGMO) - Get Sangamo Therapeutics, Inc. Report reported a narrower-than-expected loss for the latest third quarter.

Excluding certain noncash charges, the loss for the third quarter was $561,000, or 3 cents a share. According to a

First Call/Thomson Financial

consensus estimate, six analysts were looking for a loss of 5 cents a share. The company lost 7 cents a share in the year-ago period before noncash items.

TheStreet Recommends

The genetics research company said third-quarter revenue rose to $823,000 from $630,000 a year ago. The company credited its Universal GeneTools product and its partnership with

Edwards Lifesciences

(EW) - Get Edwards Lifesciences Corporation Report

as the primary revenue source during the third quarter.